Natera, Inc. (NASDAQ:NTRA) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund lowered its position in Natera, Inc. (NASDAQ:NTRA) by 20.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 58,047 shares of the medical research company’s stock after selling 14,782 shares during the quarter. New York State Common Retirement Fund’s holdings in Natera were worth $8,208,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Amalgamated Bank raised its holdings in shares of Natera by 9.8% in the first quarter. Amalgamated Bank now owns 8,293 shares of the medical research company’s stock worth $1,173,000 after acquiring an additional 740 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Natera by 32.3% in the 1st quarter. GAMMA Investing LLC now owns 848 shares of the medical research company’s stock worth $120,000 after purchasing an additional 207 shares during the last quarter. Teza Capital Management LLC acquired a new stake in shares of Natera during the 4th quarter valued at approximately $221,000. Asset Management One Co. Ltd. bought a new position in shares of Natera during the first quarter valued at approximately $6,753,000. Finally, QRG Capital Management Inc. increased its holdings in shares of Natera by 1.5% in the 1st quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company’s stock worth $766,000 after acquiring an additional 81 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Performance

Shares of Natera stock opened at $138.90 on Friday. The firm has a fifty day moving average of $160.09 and a two-hundred day moving average of $158.02. The stock has a market capitalization of $18.97 billion, a price-to-earnings ratio of -94.49 and a beta of 1.73. Natera, Inc. has a 52 week low of $92.14 and a 52 week high of $183.00.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. Natera’s revenue for the quarter was up 36.5% compared to the same quarter last year. During the same period last year, the company earned ($0.56) EPS. As a group, research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NTRA has been the topic of several analyst reports. Piper Sandler increased their price target on shares of Natera from $205.00 to $210.00 and gave the stock an “overweight” rating in a research note on Thursday, May 15th. Wall Street Zen cut Natera from a “hold” rating to a “sell” rating in a report on Saturday, May 17th. Barclays increased their price target on Natera from $160.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday, May 9th. Finally, UBS Group raised their price target on Natera from $211.00 to $218.00 and gave the stock a “buy” rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average target price of $184.63.

Insider Transactions at Natera

In other Natera news, CFO Michael Burkes Brophy sold 2,018 shares of the business’s stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $152.18, for a total value of $307,099.24. Following the completion of the sale, the chief financial officer owned 73,539 shares in the company, valued at approximately $11,191,165.02. The trade was a 2.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $166.77, for a total value of $500,310.00. Following the sale, the insider owned 130,205 shares in the company, valued at approximately $21,714,287.85. This trade represents a 2.25% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 53,272 shares of company stock valued at $8,345,368 over the last three months. Corporate insiders own 7.60% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.